What Biological Mechanism Allows 1064Nm Nd:yag Lasers To Reduce Keloids, And What Operational Precautions Must Clinicians Take To Prevent Scar Recurrence?

1064 nm Nd:YAG lasers reduce keloids primarily by damaging the lesion’s deep dermal microvasculature. Hemoglobin absorbs the laser’s thermal energy, producing controlled intravascular coagulation and reduced blood flow. The resulting hypoperfusion and hypoxia suppress fibroblast activity and excessive collagen production while normal collagen breakdown continues, allowing the keloid to progressively flatten, soften, and become less erythematous.

The therapeutic principle is controlled vascular injury without creating an open wound. Excessive heating that causes coagulation, charring, ulceration, or sloughing can stimulate secondary-intention healing and substantially increase the risk of recurrent or more aggressive keloid formation.

How the Laser Changes Keloid Biology

Deep dermal vascular targeting

The 1064 nm wavelength penetrates relatively deeply into the dermis with limited scattering. Its thermal effect is directed in part toward hemoglobin-containing microvessels that support the highly vascular keloid.

When these vessels undergo controlled coagulation, the lesion’s microcirculation is reduced. This deprives the scar tissue of the vascular support needed to sustain continued fibroblast proliferation and collagen deposition.

Hypoperfusion suppresses collagen overproduction

Reduced perfusion creates a local environment of hypoxia and lower metabolic support. This can reduce pro-fibrotic signaling, including activity associated with transforming growth factor-beta 1, while favoring matrix-remodeling processes.

The central therapeutic balance is important: collagen synthesis decreases, but collagenolytic activity is preserved or relatively enhanced. Over time, this favors breakdown and reorganization of the excessive collagen bundles that make the keloid raised and firm.

Fibroblast and inflammatory signaling effects

The laser’s deep thermal effect can inhibit keloid fibroblast proliferation and reduce signaling that drives persistent inflammation and matrix accumulation. These effects complement the vascular response rather than replacing it.

The clinical result is typically gradual. Flattening, softening, and reduction in redness generally require a series of carefully controlled treatments rather than a single aggressive exposure.

Why Treatment Precision Determines the Outcome

The goal is controlled heating

Clinicians must deliver enough energy to affect abnormal dermal vessels and scar tissue without producing visible destructive injury. The treatment endpoint should reflect adequate vascular response, such as delayed reperfusion, rather than tissue whitening, coagulation, or burning.

Settings must be individualized according to lesion thickness, vascularity, color, treatment mode, and the patient’s skin characteristics. More erythematous lesions may absorb thermal energy more readily and therefore require conservative energy selection.

Protect the epidermis during delivery

Continuous surface cooling is important during transcutaneous treatment because it protects the epidermis while allowing the deeper target to receive thermal energy. Cooling technique and equipment must be applied consistently throughout laser delivery.

Clinicians should also verify that the selected pulse duration, power, spot size, and delivery mode are appropriate for the device and lesion. Generic settings cannot be transferred safely between systems or patients.

Avoid blanching and coagulation points

Visible blanching, focal coagulation, or other signs of excessive thermal injury indicate that the tissue may be receiving more energy than intended. Treatment should be adjusted before these endpoints progress to necrosis.

The objective is vascular shutdown and prolonged reperfusion time, not surface destruction. Operators should document the tissue response and use it to guide later sessions.

How to Reduce Post-Treatment Recurrence

Prevent charring and tissue necrosis

Power levels and pulse delivery must be precisely controlled in both transcutaneous and interstitial approaches. Epidermal charring, frank coagulation, and excessive blanching should be treated as preventable complications, not acceptable indicators of efficacy.

Thermal injury that extends beyond the intended target can destroy viable tissue and compromise healing. This creates conditions that may reactivate the same fibrotic process the treatment was intended to suppress.

Avoid ulceration and sloughing

Over-treatment can cause tissue infarction, ulceration, and sloughing. When the wound heals by secondary intention, prolonged inflammation and abnormal repair signaling may encourage aggressive keloid recurrence.

For this reason, treatment should remain non-destructive whenever the clinical protocol calls for transcutaneous vascular remodeling. Any unexpected ulceration or necrosis requires appropriate wound assessment and management.

Consider early low-fluence treatment after surgery

Patients with a strong tendency toward keloid formation may benefit from an early postoperative strategy using conservative laser therapy, when clinically appropriate. The rationale is to suppress excessive vascularization before a mature recurrent keloid becomes established.

Timing must account for wound integrity, surgical site, infection risk, skin type, and the broader scar-management plan. Laser therapy should be integrated with, rather than substituted for, appropriate postoperative follow-up and other evidence-based measures.

Understanding the Trade-offs

More energy does not mean better control

Increasing energy to obtain a dramatic immediate response can produce unnecessary tissue destruction. A visibly injured surface may represent excessive treatment rather than successful keloid control.

The desired effect is progressive remodeling through controlled vascular and fibroblast suppression. That process is slower but generally more compatible with preserving the epidermis and reducing wound-related recurrence risk.

Recurrence cannot be eliminated by laser technique alone

Keloids are biologically prone to recur, and recurrence depends on factors such as lesion location, tension, genetics, prior treatment, inflammation, and wound healing. Careful laser operation reduces avoidable treatment-related risk but cannot guarantee permanent clearance.

Patients should therefore be monitored over time, particularly after surgery or treatment of a previously recurrent lesion. A combined scar-management plan may be necessary for higher-risk cases.

Treatment protocols require clinical judgment

Published protocols may describe power ranges, pulse modes, cooling methods, and session intervals, but those parameters are device-specific and patient-specific. They should not be treated as universal prescriptions.

Treatment is commonly staged over multiple sessions with several weeks between exposures, allowing clinicians to assess healing and vascular response before delivering additional energy. The exact schedule must be determined by a qualified operator using the specific laser platform.

Making the Right Choice for Your Goal

The operational principle is to achieve deep vascular control while preserving viable surface tissue and orderly wound healing.

If your primary focus is reducing keloid thickness and redness: Target the deep dermal microvasculature with controlled thermal exposure and assess response through delayed reperfusion rather than visible tissue destruction.
If your primary focus is preventing recurrence after surgery: Consider an early, conservative postoperative strategy for high-risk patients, provided the wound is suitable and the plan is supervised by an experienced clinician.
If your primary focus is treatment safety: Use individualized settings, continuous epidermal cooling where appropriate, and immediate adjustment when blanching, coagulation, charring, ulceration, or sloughing appears.
If your primary focus is durable control: Treat laser therapy as part of longitudinal scar management, because keloid biology and recurrence risk extend beyond vascular treatment alone.

The safest and most effective approach is controlled dermal vascular injury without converting the keloid into an open wound.

Summary Table:

Mechanism	Operational Precautions
Deep dermal vascular targeting: Hemoglobin absorption causes controlled coagulation, reducing blood flow and suppressing fibroblasts.	Use individualized settings; protect epidermis with continuous cooling. Avoid blanching, coagulation, and charring.
Hypoperfusion reduces collagen overproduction: Hypoxia inhibits TGF-β1 signaling, decreasing collagen synthesis while preserving breakdown.	Adjust energy to achieve delayed reperfusion, not tissue destruction. Document tissue response for guidance.
Fibroblast and inflammatory signaling effects: Thermal effect inhibits fibroblast proliferation and reduces pro-fibrotic inflammation.	Prevent ulceration and sloughing; treat any necrosis promptly. Consider early low-fluence postoperative treatment for high-risk patients.

Elevate your clinic's keloid treatment outcomes with BELIS's advanced 1064nm Nd:YAG laser systems, designed specifically for clinics and premium salons. Our cutting-edge technology ensures precise vascular targeting with optimal safety, helping you achieve superior results and reduce recurrence. Contact us today to schedule a consultation and discover how BELIS can empower your practice. Contact us now.